GovWire

In this statement, the Competition and Markets Authority (CMA) clarifies the circumstances under which it will not prioritise enforcement action against drug firms when they implement a specific negotiation framework to make more combination therapies available on the NHS.

The CMAs statement applies only where certain market features are present and particular conditions are met.

Combination therapies are treatments using 2 or more medicines in combination.